Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
LEXINGTON, Mass. , April 9, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that John Sheppard ,
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
LEXINGTON, Mass. , April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first
View HTML
Toggle Summary Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
- Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations - Key secondary endpoint of clinically relevant two-point ocular itch score improvement achieved for both tested reproxalap concentrations - Company closed on $60 million term loan
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
LEXINGTON, Mass. , March 25, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast
View HTML
Toggle Summary Aldeyra Therapeutics Announces Year-End 2018 Financial Results
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 - The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Disease Expected to Begin in First Half of 2019 - Results from the SOLACE Phase 3 Clinical Trial in Noninfectious Anterior Uveitis Expected in
View HTML
Toggle Summary Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
LEXINGTON, Mass. , March 1, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Friday,
View HTML
Toggle Summary Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019 Co-Primary Endpoints Confirmed for Phase 3 Clinical Trial in Dry Eye Disease, Expected to Begin in First Half of 2019 Phase 3 Clinical Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected to Begin in
View HTML
Toggle Summary Aldeyra Therapeutics to Host 2019 Research & Development Day
LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a
View HTML
Toggle Summary Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Results Expected in 2020 LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc.
View HTML
Toggle Summary Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
LEXINGTON, Mass. , Jan. 15, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to inventing, developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Stephen
View HTML